358 related articles for article (PubMed ID: 25916583)
1. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
3. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
5. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
Lim SH; Vaughan AT; Ashton-Key M; Williams EL; Dixon SV; Chan HT; Beers SA; French RR; Cox KL; Davies AJ; Potter KN; Mockridge CI; Oscier DG; Johnson PW; Cragg MS; Glennie MJ
Blood; 2011 Sep; 118(9):2530-40. PubMed ID: 21768293
[TBL] [Abstract][Full Text] [Related]
6. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
[TBL] [Abstract][Full Text] [Related]
7. IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis.
Navrátilová A; Andrés Cerezo L; Hulejová H; Bečvář V; Tomčík M; Komarc M; Veigl D; Tegzová D; Závada J; Olejárová M; Pavelka K; Vencovský J; Šenolt L
Front Immunol; 2021; 12():745523. PubMed ID: 34745117
[TBL] [Abstract][Full Text] [Related]
8. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
[TBL] [Abstract][Full Text] [Related]
9. Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.
Mota P; Reddy V; Isenberg D
Expert Rev Clin Immunol; 2017 Jul; 13(7):667-676. PubMed ID: 27841031
[TBL] [Abstract][Full Text] [Related]
10. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.
Pérez-Sánchez C; Cecchi I; Barbarroja N; Patiño-Trives AM; Luque-Tévar M; Pérez-Sánchez L; Ibáñez-Costa A; Arias de la Rosa I; Ortega R; Escudero A; Castro MC; Radin M; Roccatello D; Sciascia S; Aguirre MÁ; Collantes E; López-Pedrera C;
J Cell Mol Med; 2019 Sep; 23(9):6308-6318. PubMed ID: 31347786
[TBL] [Abstract][Full Text] [Related]
11. Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.
Vaughan AT; Chan CH; Klein C; Glennie MJ; Beers SA; Cragg MS
J Biol Chem; 2015 Feb; 290(9):5424-37. PubMed ID: 25568316
[TBL] [Abstract][Full Text] [Related]
12. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.
Mélet J; Mulleman D; Goupille P; Ribourtout B; Watier H; Thibault G
Arthritis Rheum; 2013 Nov; 65(11):2783-90. PubMed ID: 23918413
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
15. B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
Favas C; Isenberg DA
Nat Rev Rheumatol; 2009 Dec; 5(12):711-6. PubMed ID: 19946298
[TBL] [Abstract][Full Text] [Related]
16. Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
Reddy VR; Pepper RJ; Shah K; Cambridge G; Henderson SR; Klein C; Kell L; Taylor SJ; Isenberg DA; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2022 Jul; 61(7):2894-2904. PubMed ID: 34788412
[TBL] [Abstract][Full Text] [Related]
17. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
18. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.
Nakou M; Katsikas G; Sidiropoulos P; Bertsias G; Papadimitraki E; Raptopoulou A; Koutala H; Papadaki HA; Kritikos H; Boumpas DT
Arthritis Res Ther; 2009; 11(4):R131. PubMed ID: 19715572
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
Dass S; Vital EM; Emery P
Expert Opin Pharmacother; 2006 Dec; 7(18):2559-70. PubMed ID: 17150009
[TBL] [Abstract][Full Text] [Related]
20. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
